Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ISRCTN15146958) titled 'A study of nipocalimab in adults with moderate to severe systemic lupus erythematosus' on March 13.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Parallel
Purpose: Treatment, Safety
Primary Sponsor: Janssen-Cilag International NV
Condition:
Systemic lupus erythematosus
Musculoskeletal Diseases
Intervention:
Experimental: Nipocalimab
Participants will receive nipocalimab up to Week 52 in the double-blind treatment period along with standard of care treatments. At Week 52, eligible participants will have the optio...